Assenagon Asset Management S.A. lessened its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 50.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 229,438 shares of the company’s stock after selling 231,403 shares during the period. Assenagon Asset Management S.A.’s holdings in AstraZeneca were worth $15,925,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AZN. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca in the 1st quarter valued at $28,000. Panagora Asset Management Inc. raised its holdings in shares of AstraZeneca by 55.1% in the 1st quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company’s stock valued at $793,000 after purchasing an additional 4,249 shares in the last quarter. BlackRock Inc. raised its holdings in shares of AstraZeneca by 22.0% in the 1st quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock valued at $495,328,000 after purchasing an additional 1,343,939 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in shares of AstraZeneca by 102.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock valued at $36,000 after purchasing an additional 266 shares in the last quarter. Finally, Moors & Cabot Inc. raised its holdings in shares of AstraZeneca by 2.8% in the 1st quarter. Moors & Cabot Inc. now owns 10,841 shares of the company’s stock valued at $719,000 after purchasing an additional 292 shares in the last quarter. Hedge funds and other institutional investors own 16.07% of the company’s stock.
AstraZeneca Trading Up 1.0 %
Shares of AstraZeneca stock opened at $71.57 on Friday. AstraZeneca PLC has a 1 year low of $52.65 and a 1 year high of $76.56. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.70 and a current ratio of 0.90. The company has a market capitalization of $221.85 billion, a P/E ratio of 47.09, a PEG ratio of 1.41 and a beta of 0.52. The company’s fifty day moving average is $73.61 and its two-hundred day moving average is $70.28.
Analyst Ratings Changes
A number of brokerages have recently weighed in on AZN. Morgan Stanley upgraded shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a report on Tuesday, April 11th. Argus cut their price target on shares of AstraZeneca from $85.00 to $80.00 in a research note on Friday, May 26th. Finally, StockNews.com assumed coverage on shares of AstraZeneca in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $103.00.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Featured Articles
- Five stocks we like better than AstraZeneca
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
- SMART Global Holdings Momentum, Room To Move Higher?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
